PHASE-III RANDOMIZED STUDY OF ZOLADEX VERSUS STILBESTROL IN THE TREATMENT OF ADVANCED PROSTATE-CANCER

被引：33

作者：

WAYMONT, B

LYNCH, TH

DUNN, JA

EMTAGE, LA

ARKELL, DG

WALLACE, DMA

BLACKLEDGE, GRP

机构：

[1] WALSGRAVE GEN HOSP, COVENTRY CV2 2DY, W MIDLANDS, ENGLAND

[2] DUDLEY RD GEN HOSP, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND

[3] UNIV BIRMINGHAM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND

来源：

BRITISH JOURNAL OF UROLOGY | 1992年 / 69卷 / 06期

关键词：

D O I：

10.1111/j.1464-410X.1992.tb15633.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

An open randomised Phase III trial was conducted of the depot GnRH analogue goserelin (Zoladex) versus stilboestrol (3 mg/day) in patients with advanced or metastatic prostate cancer. The study included 250 patients and the median follow-up was 43 months. In the Zoladex arm the time to first response was achieved earlier and more patients reported an improvement in symptoms. There was no statistically significant difference between the Zoladex and the stilboestrol arms with regard to survival and time to treatment failure. A major reason for treatment failure was the preponderance of adverse events in patients receiving stilboestrol. It is suggested that stilboestrol should no longer be used for prostate cancer when equally effective alternative treatments are available.

引用

页码：614 / 620

页数：7

共 18 条

[1]

BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO

[2]

2-9

[3] THE TREATMENT OF METASTATIC PROSTATIC-CANCER WITH THE SLOW RELEASE LH-RH ANALOG ZOLADEX-ICI-118630 [J].

BEACOCK, CJ ;

BUCK, AC ;

ZWINCK, R ;

PEELING, WB ;

REES, RWM ;

TURKES, A ;

WALKER, K ;

GRIFFITHS, K .

BRITISH JOURNAL OF UROLOGY, 1987, 59 (05) :436-442

[4]

BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO

[5]

2-C

[6]

CHISHOLM GD, 1980, TUTORIALS POST GRADU, V15, P243

[7] LONG-TERM THERAPY WITH A DEPOT LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG (ZOLADEX) IN PATIENTS WITH ADVANCED PROSTATIC-CARCINOMA [J].

DEBRUYNE, FMJ ;

DENIS, L ;

LUNGLMAYER, G ;

MAHLER, C ;

NEWLING, DWW ;

RICHARDS, B ;

ROBINSON, MRG ;

SMITH, PH ;

WEIL, EHJ ;

WHELAN, P .

JOURNAL OF UROLOGY, 1988, 140 (04) :775-777

[8] HEMOSTATIC CHANGES DURING HORMONE MANIPULATION IN ADVANCED PROSTATE-CANCER - A COMPARISON OF DES 3-MG DAY AND GOSERELIN 3.6-MG MONTH [J].

EMTAGE, LA ;

GEORGE, J ;

BOUGHTON, BJ ;

TRETHOWAN, C ;

BLACKLEDGE, GRP .

EUROPEAN JOURNAL OF CANCER, 1990, 26 (03) :315-319

[9]

GARNICK MB, 1984, NEW ENGL J MED, V311, P1281

[10] Studies on prostatic cancer III The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate [J].

Huggins, C ;

Scott, WW ;

Hodges, CV .

JOURNAL OF UROLOGY, 1941, 46 (05) :997-1006

← 1 2 →